The role of PD-1/PD-L1 pathway in ulcerative colitis and changes following tonsil-derived mesenchymal stem cells treatment
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: The programmed death 1 (PD-1)/programmed death-ligand 1 (PD-L1) pathway has not been fully evaluated in inflammatory bowel disease. We evaluated PD-1/PD-L1 levels in patients with ulcerative colitis (UC) and their significance in tonsil-derived mesenchymal stem cells (TMSCs) treatment. Methods: Using acute and chronic murine colitis model, we measured the PD-1 and PD-L1 levels in inflamed colonic tissues pre- and post-treatment with TMSCs. We also measured PD-1 and PD-L1 levels in colonic tissues from UC patients, compared to normal controls. Results: In the analysis using human colonic tissues, a significant increase in the levels of PD-1 and PD-L1 was observed in the colonic mucosa of patients with UC compared with normal controls (p < 0.001 and p = 0.005, respectively). When comparing the maximal disease extent, PD-L1 levels were highest in patients with proctitis (38.5 ± 46.7), followed by left-side colitis (17.5 ± 23.1) and extensive colitis (5.2 ± 8.2) (p < 0.001). In the chronic colitis model, the level of PD-L1 was decreased (p = 0.040) and the level of PD-1 increased more than in normal controls (p = 0.047). After treatment with TMSC, significant improvements were observed in body weight, disease activity index, and colon length recovery. Additionally, the levels of PD-1 and PD-L1 were recovered; PD-L1 significantly increased (p = 0.031), while the level of PD-1 decreased (p = 0.310). Conclusions: The altered expression of PD-1 and PD-L1 in colonic mucosa may be a possible mechanism of UC, and T-MSC-derived PD-L1 could help suppress colitis.
Abstract
Background/Aims: The programmed death 1 (PD-1)/programmed death-ligand 1 (PD-L1) pathway has not been fully evaluated in inflammatory bowel disease. We evaluated PD-1/PD-L1 levels in patients with ulcerative colitis (UC) and their significance in tonsil-derived mesenchymal stem cells (TMSCs) treatment. Methods: Using acute and chronic murine colitis model, we measured the PD-1 and PD-L1 levels in inflamed colonic tissues pre- and post-treatment with TMSCs. We also measured PD-1 and PD-L1 levels in colonic tissues from UC patients, compared to normal controls. Results: In the analysis using human colonic tissues, a significant increase in the levels of PD-1 and PD-L1 was observed in the colonic mucosa of patients with UC compared with normal controls (p < 0.001 and p = 0.005, respectively). When comparing the maximal disease extent, PD-L1 levels were highest in patients with proctitis (38.5 ± 46.7), followed by left-side colitis (17.5 ± 23.1) and extensive colitis (5.2 ± 8.2) (p < 0.001). In the chronic colitis model, the level of PD-L1 was decreased (p = 0.040) and the level of PD-1 increased more than in normal controls (p = 0.047). After treatment with TMSC, significant improvements were observed in body weight, disease activity index, and colon length recovery. Additionally, the levels of PD-1 and PD-L1 were recovered; PD-L1 significantly increased (p = 0.031), while the level of PD-1 decreased (p = 0.310). Conclusions: The altered expression of PD-1 and PD-L1 in colonic mucosa may be a possible mechanism of UC, and T-MSC-derived PD-L1 could help suppress colitis.
참고문헌 (24)
- Mak WY, "The epidemiology of inflammatory bowel disease : east meets west", J Gastroenterol Hepatol, 35, pp.380~389 (2020)
- Park SH, "A 30-year trend analysis in the epidemiology of inflammatory bowel disease in the Songpa-Kangdong district of Seoul, Korea in 1986-2015", J Crohns Colitis, 13, pp.1410~1417 (2019)
- Guan Q, "A comprehensive review and update on the pathogenesis of inflammatory bowel disease", J Immunol Res, 2019, pp.7247238~ (2019)
- Keir ME, "PD-1 and its ligands in tolerance and immunity", Annu Rev Immunol, 26, pp.677~704 (2008)
- Kim JY, "Tonsil-derived mesenchymal stem cells(T-MSCs)prevent Th17-mediated autoimmune response via regulation of the programmed death-1", programmed death ligand-1(PD-1, J Tissue Eng Regen Med, pp.2018, 12[DOI]
- Beswick EJ, "Expression of programmed death-ligand 1 by human colonic CD90+ stromal cells differs between ulcerative colitis and Crohn’s disease and determines their capacity to suppress Th1 cells", Front Immunol, 9, pp.1125~ (2018)
- Kanai T, "Blockade of B7-H1suppresses the development of chronic intestinal inflammation", J Immunol, 171, pp.4156~4163 (2003)
- Scandiuzzi L, "Tissue-expressed B7-H1 critically controls intestinal inflammation", Cell Rep, 6, pp.625~632 (2014)
- Park SJ, "PD-1deficiency protects experimental colitis via alteration of gut microbiota", BMB Rep, 50, pp.578~583 (2017)
- Flores AI, "Stem cell therapy in inflammatory bowel disease : a promising therapeutic strategy?", World J Stem Cells, 7, pp.343~351 (2015)
- Ciccocioppo R, "Autologous bone marrow-derived mesenchymal stromal cells in the treatment of fistulising Crohn’s disease", Gut, 60, pp.788~798 (2011)
- Janjanin S, "Human palatine tonsil : a new potential tissue source of multipotent mesenchymal progenitor cells", Arthritis Res Ther, 10, pp.R83~ (2008)
- Oh SY, "Application of tonsil-derived mesenchymal stem cells in tissue regeneration : concise review", Stem Cells, 37, pp.1252~1260 (2019)
- Yu Y, "Therapeutic potential of tonsil-derived mesenchymal stem cells in dextran sulfate sodium-induced experimental murine colitis", PLoS One, 12, pp.e0183141~ (2017)
- Lee KE, "The efficacy of conditioned medium released by tonsil-derived mesenchymal stem cells in a chronic murine colitis model", PLoS One, 14, pp.e0225739~ (2019)
- Dominici M, "Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement", Cytotherapy, 8, pp.315~317 (2006)
- Yu Y, "Characterization of long-term in vitro culture-related alterations of human tonsil-derived mesenchymal stem cells : role for CCN1 in replicative senescence-associated increase in osteogenic differentiation", J Anat, 225, pp.510~518 (2014)
- Rajabian Z, "Over-expression of immunosuppressive molecules, PD-L1 and PD-L2, in ulcerative colitis patients", Iran J Immunol, 16, pp.62~70 (2019)
- Nguyen J, "Overexpression of programmed death ligand 1 in refractory inflammatory bowel disease", Hum Pathol, 126, pp.19~27 (2022)
- Zhou L, "Bifidobacterium infantis induces protective colonic PD-L1 and Foxp3 regulatory T cells in an acute murine experimental model of inflammatory bowel disease", Gut Liver, 13, pp.430~439 (2019)
- Zhou LY, "Bifidobacterium infantis regulates the programmed cell death 1 pathway and immune response in mice with inflammatory bowel disease", World J Gastroenterol, 28, pp.3164~3176 (2022)
- Song MY, "Protective effects of Fcfused PD-L1 on two different animal models of colitis", Gut, 64, pp.260~271 (2015)
- Silva FA, "The immunological basis of inflammatory bowel disease", Gastroenterol Res Pract, 2016, pp.2097274~ (2016)
- Kolls JK, "Interleukin-17 family members and inflammation", Immunity, 21, pp.467~476 (2004)